You are here:
Home
NICE Guidance
Conditions and diseases
Mental health, behavioural and neurodevelopmental conditions
Dementia
Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]
Topic prioritisation
Project information
Project documents
33806-Donanemab-for-Alzheimers-Disease-V1.0-SEP2025-NON-CONF.pdf
Back to top